Bo Huang
Pfizer (United States)(US)
Publications by Year
Research Areas
Statistical Methods in Clinical Trials, Cancer Immunotherapy and Biomarkers, Renal cell carcinoma treatment, Advanced Causal Inference Techniques, Health Systems, Economic Evaluations, Quality of Life
Most-Cited Works
- → Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma(2019)2,502 cited
- → Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma(2020)1,443 cited
- → Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma(2013)812 cited
- → Improving power and accuracy of genome-wide association studies via a multi-locus mixed linear model methodology(2016)535 cited
- → Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma(2020)454 cited
- → Methodological implementation of mixed linear models in multi-locus genome-wide association studies(2016)400 cited
- → Phase II Study of the Anti-Cytotoxic T-Lymphocyte–Associated Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal Cancer(2010)304 cited
- → Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer(2018)274 cited
- → Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors(2017)229 cited
- → A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer(2014)217 cited